SAN DIEGO--(BUSINESS WIRE)--SynteractHCR, a full-service, international contract research organization (CRO), announces that its vice president for global medical and regulatory affairs, Dr. Martine Dehlinger-Kremer, has been elected president of the European CRO Federation. Representing over 300 CROs with over 20,000 employees in 18 countries, EUCROF is a non-profit organization created to promote clinical research by improving the knowledge, competence and skills of CROs in Europe.
Dehlinger-Kremer’s responsibilities will include ensuring the mission of EUCROF, representing the Federation, further developing its educational activities and ensuring its further expansion. She will continue to serve as chair of the EUCROF Paediatric Working Group, a position she has successfully held since 2008, and will remain an executive team member of SynteractHCR’s global operating committee.
“Dr. Dehlinger-Kremer has shown her commitment to advancing clinical research throughout her career. She exemplifies our mission at SynteractHCR of developing a better future for patients by bringing expertise to clinical development – and this additional position at EUCROF furthers that goal. We congratulate her on this honor and recognition of her expertise,” said Wendel Barr, CEO of SynteractHCR.
Former EUCROF president, Dr. Stefano Marini of Italy, who served a full three terms allowed in the role per bylaws, will now be vice president. Other board members elected on 30 November include: Secretary Simon Lee (UK), Treasurer Yoani Matsakis (France - re-elected), Member Christophe Golenvaux (Belgium - re-elected).
Founded in 2005, EUCROF represents and supports the interest of CROs towards the healthcare-related industry within the field of clinical research, as well as the medical and affiliated research community. It is recognized by regulatory authorities as the representative for European based CROs and is regularly consulted to contribute to the improvement of rules and regulations. Its members hail from Belgium, Czech Republic, France, Germany, Greece, Italy, Slovak Republic, Spain, Sweden, the Netherlands, Turkey, and the UK. Associate members are from Austria, Bulgaria, Denmark, Portugal, Switzerland and Ukraine.
Dehlinger-Kremer has more than 30 years of experience in the clinical research industry and has contributed to the global development of numerous pharmaceutical products and devices, including participating in 100+ NDAs/MAAs. She was also recently appointed chair of the European Forum for Good Clinical Practice (EFGCP) Children’s Medicines Working Party and a member of the EFGCP Board and has been a member of the Enpr-EMA working groups, Paediatric Network at EMA since 2013. She is also a member of the EMA’s Task Force, “EU Clinical Trials Portal and Data Base,” for the implementation of the EU Clinical Trials Regulation. In August 2015, Dehlinger-Kremer was named one of PharmaVOICE Magazine’s “100 Most Inspiring People in Life Sciences.”
“I am honored to be entrusted by EUCROF members with this election as president,” said Dehlinger-Kremer. “I look forward to working with the board and all members to further the Federation’s vision as a key institution in contributing to the development of better medicines for patients through CRO knowledge and expertise. We will collaborate with authorities, partner with pharma and patient associations, and expand the training role for CROs to further EUCROF’s mission.”
SynteractHCR is a full-service contract research organization with a successful two-decade track record supporting biotechnology, medical device and pharmaceutical companies in all phases of clinical development. SynteractHCR has conducted Phase I-IV studies on six continents and 60 countries, offering expertise across multiple therapeutic areas, with notable depth in oncology, immunotherapy, CNS, infectious disease, endocrinology, cardiovascular and respiratory, among other indications. With its “Shared Work – Shared Vision” philosophy, SynteractHCR provides customized services collaboratively and cost effectively, ensuring on-time delivery of quality data to help bring tomorrow’s treatments to patients.